These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35001204)

  • 61. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
    Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Voretigene neparvovec-rzyl for treatment of
    Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
    Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
    [No Abstract]   [Full Text] [Related]  

  • 63. Surgical Observations From the First 120 Cases of Subretinal Gene Therapy for Inherited Retinal Diseases.
    Gregori NZ; Davis JL
    Retina; 2023 Sep; 43(9):1608-1611. PubMed ID: 33394965
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Could internal limiting membrane peeling before Voretigen neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy?
    Dormegny L; Studer F; Sauer A; Ballonzoli L; Speeg-Schatz C; Bourcier T; Dollfus H; Gaucher D
    Heliyon; 2024 Feb; 10(3):e25154. PubMed ID: 38322949
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.
    Gardiner KL; Cideciyan AV; Swider M; Dufour VL; Sumaroka A; Komáromy AM; Hauswirth WW; Iwabe S; Jacobson SG; Beltran WA; Aguirre GD
    Mol Ther; 2020 Jan; 28(1):266-278. PubMed ID: 31604676
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations.
    Paunescu K; Wabbels B; Preising MN; Lorenz B
    Graefes Arch Clin Exp Ophthalmol; 2005 May; 243(5):417-26. PubMed ID: 15565294
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A high prevalence of biallelic RPE65 mutations in Costa Rican children with Leber congenital amaurosis and early-onset retinal dystrophy.
    Glen WB; Peterseim MMW; Badilla R; Znoyko I; Bourg A; Wilson R; Hardiman G; Wolff D; Martinez J
    Ophthalmic Genet; 2019 Apr; 40(2):110-117. PubMed ID: 30870047
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.
    Johnson S; Buessing M; O'Connell T; Pitluck S; Ciulla TA
    JAMA Ophthalmol; 2019 Oct; 137(10):1115-1123. PubMed ID: 31318398
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intraperitoneal chromophore injections delay early-onset and rapid retinal cone degeneration in a mouse model of Leber congenital amaurosis.
    Dai X; Jin X; Ye Q; Huang H; Duo L; Lu C; Bao J; Chen H
    Exp Eye Res; 2021 Nov; 212():108776. PubMed ID: 34582935
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.
    Cideciyan AV; Hauswirth WW; Aleman TS; Kaushal S; Schwartz SB; Boye SL; Windsor EA; Conlon TJ; Sumaroka A; Pang JJ; Roman AJ; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2009 Sep; 20(9):999-1004. PubMed ID: 19583479
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pseudo-fovea formation after gene therapy for RPE65-LCA.
    Cideciyan AV; Aguirre GK; Jacobson SG; Butt OH; Schwartz SB; Swider M; Roman AJ; Sadigh S; Hauswirth WW
    Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):526-37. PubMed ID: 25537204
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Natural History of Leber Congenital Amaurosis and Cone-Rod Dystrophy Associated with Variants in the GUCY2D Gene.
    Hahn LC; Georgiou M; Almushattat H; van Schooneveld MJ; de Carvalho ER; Wesseling NL; Ten Brink JB; Florijn RJ; Lissenberg-Witte BI; Strubbe I; van Cauwenbergh C; de Zaeytijd J; Walraedt S; de Baere E; Mukherjee R; McKibbin M; Meester-Smoor MA; Thiadens AAHJ; Al-Khuzaei S; Akyol E; Lotery AJ; van Genderen MM; Ossewaarde-van Norel J; van den Born LI; Hoyng CB; Klaver CCW; Downes SM; Bergen AA; Leroy BP; Michaelides M; Boon CJF
    Ophthalmol Retina; 2022 Aug; 6(8):711-722. PubMed ID: 35314386
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
    Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
    Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy.
    Cideciyan AV
    Prog Retin Eye Res; 2010 Sep; 29(5):398-427. PubMed ID: 20399883
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Available Evidence on Leber Congenital Amaurosis and Gene Therapy.
    Alkharashi M; Fulton AB
    Semin Ophthalmol; 2017; 32(1):14-21. PubMed ID: 27686653
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study.
    Talib M; van Schooneveld MJ; van Genderen MM; Wijnholds J; Florijn RJ; Ten Brink JB; Schalij-Delfos NE; Dagnelie G; Cremers FPM; Wolterbeek R; Fiocco M; Thiadens AA; Hoyng CB; Klaver CC; Bergen AA; Boon CJF
    Ophthalmology; 2017 Jun; 124(6):884-895. PubMed ID: 28341475
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect.
    Leroy BP; Fischer MD; Flannery JG; MacLaren RE; Dalkara D; Scholl HPN; Chung DC; Spera C; Viriato D; Banhazi J
    Ophthalmic Res; 2023; 66(1):179-196. PubMed ID: 36103843
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mutations in RD3 are associated with an extremely rare and severe form of early onset retinal dystrophy.
    Preising MN; Hausotter-Will N; Solbach MC; Friedburg C; Rüschendorf F; Lorenz B
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3463-72. PubMed ID: 22531706
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study.
    Fischer MD; Simonelli F; Sahni J; Holz FG; Maier R; Fasser C; Suhner A; Stiehl DP; Chen B; Audo I; Leroy BP;
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254722
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.